At HRC Fertility, innovation is not just a concept, it is what sets us apart from other providers. Under the leadership of our Director of Clinical Research, Robert Boostanfar, MD, FACOG, HRC Fertility is one of a select number of practices in the United States actively leading advanced fertility research at the highest level.
Dr. Boostanfar currently serves as the principal investigator on multiple Phase III FDA clinical trials, placing HRC Fertility at the forefront of the next generation of infertility medicine.
These studies are designed to improve outcomes while reducing the physical, emotional, and financial burden of traditional fertility treatments, expanding options for people who are trying to build their families. Unlike most fertility centers, HRC Fertility is advancing innovation across all aspects of care:
This comprehensive approach ensures patients have access to the most advanced treatment options available, often years before they become widely accessible.
Due to Dr. Boostanfar’s venerable reputation in research and clinical care, HRC Fertility is proud to be one of the few centers nationwide to lead multiple advanced clinical trials in reproductive medicine.
These studies represent the future of fertility care, focusing on safer, more effective, and more accessible treatment options.
Research Study For a New Approach to IVF
Learn about a no-cost investigational treatment that may improve the outcomes of assisted reproductive technology (ART) to become pregnant.
The GAMETO study is evaluating a groundbreaking approach to in vitro fertilization known as in vitro maturation (IVM), designed to dramatically reduce the physical burden of treatment.
Traditional IVF requires significant hormonal stimulation. The GAMETO trial introduces an innovative alternative:
This study represents a major step toward making IVF safer, simpler, and more patient-friendly.
For more information or to learn if you are eligible for the study, click here.
Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth with Frozen Embryo Transfer
The GRACE study focuses on evaluating a new biosimilar medication used during IVF treatment.
Grace Study
Medication is one of the most significant components of IVF. This study aims to:
By studying next-generation medications, HRC is helping shape future IVF protocols that are:
For more information or to learn if you are eligible for the study, click here.
Dr. Robert Boostanfar has spent over two decades at the forefront of reproductive medicine, combining clinical care with groundbreaking research.
Among Dr. Boostanfar’s many accomplishments, he has:
His work continues to focus on one goal: improving success rates while reducing the burden of treatment for patients.
